

Rabies virus - Pipeline Insight, 2021

<https://marketpublishers.com/r/R86BD132EB89EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: R86BD132EB89EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Rabies virus - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Rabies virus Understanding

Rabies virus: Overview

Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death.

"Rabies virus - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies virus pipeline landscape is provided which includes the disease overview and Rabies virus treatment guidelines. The assessment part of the report embraces, in depth Rabies virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Rabies virus R&D. The therapies under development are focused on novel approaches to treat/improve Rabies virus.

Rabies virus Emerging Drugs Chapters

This segment of the Rabies virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rabies virus Emerging Drugs

SYN-023: Synermore Biologics

Synermore's lead drug candidate, SYN-023, is a conglomerate of two anti-rabies humanized monoclonal antibodies CTB-011, and CTB-012. The drug binds to two different antigenic sites on rabies glycoprotein which results in virus neutralization in a similar mechanism by which immune response of the body neutralize the foreign antigen by producing antibodies. The drug has demonstrated good efficacy in its Phase I and Phase II trials. It has been designated with an orphan drug status for rabies.

PIKA adjuvant based rabies vaccine: Yisheng Biopharma

Yisheng's "breakthrough" drug PIKA is an adjuvant based rabies vaccine which consist of biologic complexes that are agonist to TLR3, RIG-I, and MDA5 pathways. It is an analog of double stranded RNA that interacts with TLR3 when delivered with

relevant protein based molecule. Phase I study of the molecule has demonstrated good safety and efficacy. Also, the drug has enhanced the humoral and cellular immunity.

Further product details are provided in the report.....

Rabies virus: Therapeutic Assessment

This segment of the report provides insights about the different Rabies virus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rabies virus

There are approx. 10+ key companies which are developing the therapies for Rabies virus. The companies which have their Rabies virus drug candidates in the most advanced stage, i.e. phase III include, Synermore Biologics.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Rabies virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rabies virus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies virus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger,

licensing along with a thorough therapeutic assessment of emerging Rabies virus drugs.

Rabies virus Report Insights

Rabies virus Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Rabies virus Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Rabies virus drugs?

How many Rabies virus drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rabies virus?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rabies virus

therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Rabies virus and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Synermore Biologics

CureVAC AG

Yisheng Biopharma

Sanofi Pasteur

GlaxoSmithKline

Key Products

SYN-023

CV7202

PIKA

Verorabvax

GSK3903133A

Contents

Introduction

Executive Summary

Rabies virus: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Rabies virus – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Rabies virus companies' collaborations, Licensing, Acquisition -Deal Value Trends

Rabies virus Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SYN 023: Synermore Biologics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

PIKA: Yisheng Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Rabies virus Key Companies

Rabies virus Key Products

Rabies virus- Unmet Needs

Rabies virus- Market Drivers and Barriers

Rabies virus- Future Perspectives and Conclusion

Rabies virus Analyst Views

Rabies virus Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Rabies virus

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Rabies virus
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Rabies virus - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/R86BD132EB89EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R86BD132EB89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970